Harrow (NASDAQ:HROW) Stock Falls 5.7% – What’s Next?

Harrow, Inc. (NASDAQ:HROW) shares fell 5.7% on Wednesday. The stock traded as low as $28.64 and last traded at $28.64. Approximately 307,873 shares were traded during mid-day trading, a decline of 56% from the average session volume of 696,100 shares. The stock had previously closed at $30.36.

Key Harrow News

Here’s some of the latest news about HROW:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $63 price target, implying substantial upside from the cited share price. BTIG Research ratings
• Negative Sentiment: The company lowered its full-year 2026 adjusted EBITDA outlook to more than $40 million, from prior guidance of $80 million to $100 million. It expects Q4 adjusted EBITDA above $33 million, indicating a steep step-up from Q3’s $21.2 million. Harrow Q4 and EBITDA outlook
• Negative Sentiment: Q3 GAAP net income of $9.8 million included a $5 million litigation-settlement gain, while adjusted EBITDA fell from $22.8 million a year earlier. This suggests the headline profit improvement may overstate underlying operating progress. Harrow Q3 2026 results

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on HROW shares. BTIG Research reissued a “buy” rating and set a $63.00 price objective on shares of Harrow in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research report on Friday, October 16th. Wall Street Zen raised Harrow from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Leerink Partners initiated coverage on Harrow in a research note on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target on the stock. Finally, Zacks Research lowered Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 3rd. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $66.17.

Harrow Stock Performance

The company has a debt-to-equity ratio of 19.70, a current ratio of 2.24 and a quick ratio of 2.08. The company’s fifty day simple moving average is $31.30 and its two-hundred day simple moving average is $37.74. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -37.83 and a beta of 0.18.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, November 9th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.06. The firm had revenue of $99.30 million for the quarter, compared to analyst estimates of $98.59 million. Harrow had a negative net margin of 9.39% and a negative return on equity of 68.20%. On average, analysts forecast that Harrow, Inc. will post -0.02 earnings per share for the current year.

Insider Buying and Selling at Harrow

In related news, insider Amir Shojaei sold 11,250 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $40.00, for a total value of $450,000.00. Following the sale, the insider owned 11,250 shares in the company, valued at $450,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 12.80% of the stock is owned by corporate insiders.

Institutional Trading of Harrow

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV bought a new stake in Harrow during the 1st quarter worth approximately $31,000. Sterling Capital Management LLC lifted its holdings in shares of Harrow by 836.8% in the third quarter. Sterling Capital Management LLC now owns 1,068 shares of the company’s stock valued at $33,000 after purchasing an additional 954 shares in the last quarter. First Bancorp Inc ME purchased a new position in shares of Harrow during the second quarter valued at approximately $64,000. State of Wyoming purchased a new position in shares of Harrow during the second quarter valued at approximately $72,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Harrow during the third quarter valued at approximately $59,000. 72.76% of the stock is owned by institutional investors.

Harrow Company Profile

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.